Global erythropoietin drug market is growing at a CAGR of 11.2 % during 2022-2030

Market Highlights

Erythropoietin drug are used to stimulate the growth of the RBC production. This drugs are used during treatment of cancer, renal diseases, anemia and many more. Due to changing lifestyle and adoption of smoking by majority of population has led to increase the possibility for this diseases. Increasing number of this diseases is the major driving factor for the growth of this market. Beside this introduction of new and advanced drugs and increasing demand for the treatment for the diseases like cancer and AIDS has provided fuel for the growth of this market. Global erythropoietin drug market is expected to grow at a CAGR of 11.2% and reach till 19.97 billion by 2030.

On regional basis, global erythropoietin drug market is dominated by North America. Due to presence of huge population suffering from renal diseases and cancer has helped to grow this market in North America. Europe has the second largest market slightly less then North America. UK, Germany and France are the major contributor of erythropoietin drug market in Europe. Increasing healthcare spending in this countries has provided a push to the market. Asia Pacific erythropoietin drug market is growing at a CAGR of 12.2 % during forecasted period. Due to increasing number of patients suffering from renal diseases, AIDS and cancer in this region has provided fuel for the growth of the market. Due to led development in pharmaceutical and medical sector erythropoietin drug market for Middle East and Africa is least.

Segmentation:

Global erythropoietin drug market is segmented on the basis of type of product into biosimilars, first generation formulation and second generation formulation. On the basis of application market is segmented as oncology, renal diseases, HIV and other and on the basis of end user they are segmented into hospital and pharmacy.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of  Erythropoietin Drugs Market Research Report

Competitive Analysis

The major key player for the global erythropoietin drug market are F. Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin (Japan), Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India),  Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina).

Due to increasing prevalence diseases like cancer and renal diseases across the globe many of the companies are in the race to introduce treatment. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.Hoffmann-La Roche is a Swiss multinational healthcare companyoperates under pharmaceutical and diagnostic department. This company has introduced Recormon (Epoetin-beta) in the treatment of renal anemia in patients with chronic renal failure. This is the one of the most widely used drug.

Johnson & Johnson is an American multinational medical devices and pharmaceutical manufacturing company. EPOGEN® is the most famous drug by the company.

Amgen has introduced Aranesp (darbepoetin alfa) used for the treatment of anemia in patients with kidney disease. PROCRIT® (Epoetin alfa) is also one of the famous drug of this company.

Kyowa Hakko Kirin one of the leading company for erythropoietin drug has introduced ESPO® / NESP®. ESPO® is a human erythropoietin use in treatment of renal anemia. NESP® is a long lasting erythropoiesis stimulating agent (ESA) used in treatment of renal anemia with reduced administration frequency.